Thrasos Secures $35M for Acute Kidney Injury Treatment
October 29, 2012
Share:
Bio-therapeutics company Thrasos Therapeutics has completed a $35 million financing to develop its lead product candidate for acute kidney injury, THR-184. New investor SR One led the round, and was joined by five more new investors and existing investor SW Co.
